LIGAND PHARMACEUTICALS INC — Director's Dealing 2016

Aug 3, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2016-08-01

Reporting Person: KOZARICH JOHN W (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-08-01	Common Stock	S	200.0	$135.78	Disposed	41783	Direct
2016-08-01	Common Stock	S	500.0	$137.6	Disposed	41283	Direct
2016-08-01	Common Stock	S	200.0	$138.31	Disposed	41083	Direct
2016-08-01	Common Stock	S	100.0	$139.51	Disposed	40983	Direct

Footnotes

F1: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 01, 2015, in accordance with Rule 10b5-1.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.66 to $135.89, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.16 to $137.94, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.19 to $138.43, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.